Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
$656M |
| 2 |
Bristol-Myers Squibb
BMY
|
$612M |
| 3 |
Biogen
BIIB
|
$405M |
| 4 |
UnitedHealth
UNH
|
$353M |
| 5 |
Walmart
WMT
|
$316M |
Top Sells
| 1 |
Apple
AAPL
|
$483M |
| 2 |
PepsiCo
PEP
|
$394M |
| 3 |
RHT
Red Hat Inc
RHT
|
$248M |
| 4 |
Philip Morris
PM
|
$246M |
| 5 |
Eli Lilly
LLY
|
$240M |
Sector Composition
| 1 | Healthcare | 18.91% |
| 2 | Technology | 12.35% |
| 3 | Consumer Discretionary | 10.31% |
| 4 | Financials | 9.99% |
| 5 | Consumer Staples | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $1.66B | 1.41% | 32,757,770 +12,059,163 | +58% | +$612M |
|
2
Chipotle Mexican Grill
CMG
$56.5B
| $1.61B | 1.36% | 1,914,442 +122,943 | +7% | +$103M |
|
3
VeriSign
VRSN
$25.5B
| $1.56B | 1.32% | 8,282,576 +594,300 | +8% | +$112M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $1.54B | 1.31% | 15,546,716 +6,610,931 | +74% | +$656M |
|
5
Novo Nordisk
NVO
$251B
| $1.28B | 1.08% | 24,786,716 +2,264,800 | +10% | +$117M |
|
6
Palo Alto Networks
PANW
$127B
| $1.19B | 1.01% | 5,848,150 +773,800 | +15% | +$158M |
|
|
7
Biogen
BIIB
$19.4B
| $983M | 0.83% | 4,221,206 +1,738,129 | +70% | +$405M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $982M | 0.83% | 5,799,117 +243,300 | +4% | +$41.2M |
|
9
Gilead Sciences
GILD
$140B
| $934M | 0.79% | 14,734,258 +1,994,010 | +16% | +$126M |
|
10
Meta Platforms (Facebook)
META
$1.86T
| $880M | 0.74% | 4,940,233 +1,516,372 | +44% | +$270M |
|
|
11
Walmart
WMT
$774B
| $868M | 0.73% | 7,312,737 +2,659,055 | +57% | +$316M |
|
12
Johnson & Johnson
JNJ
$427B
| $796M | 0.67% | 6,150,250 +1,809,088 | +42% | +$234M |
|
13
Starbucks
SBUX
$100B
| $784M | 0.66% | 8,868,686 -534,316 | -6% | -$47.2M |
|
14
Humana
HUM
$36.5B
| $756M | 0.64% | 2,956,318 +16,218 | +0.6% | +$4.15M |
|
15
GSK
GSK
$79.9B
| $749M | 0.63% | 17,551,699 +2,289,918 | +15% | +$97.7M |
|
16
Hershey
HSY
$37.3B
| $748M | 0.63% | 4,828,915 +588,351 | +14% | +$91.2M |
|
17
Amgen
AMGN
$155B
| $708M | 0.6% | 3,658,086 +694,848 | +23% | +$134M |
|
18
Duke Energy
DUK
$95.3B
| $704M | 0.6% | 7,344,379 -1,074,950 | -13% | -$103M |
|
19
Atlassian
TEAM
$46.6B
| $684M | 0.58% | 5,451,799 +844,199 | +18% | +$106M |
|
20
BP
BP
$90.8B
| $676M | 0.57% | 17,798,662 +5,520,860 | +45% | +$210M |
|
21
Petrobras
PBR
$79.9B
| $628M | 0.53% | 43,425,400 +3,174,400 | +8% | +$45.9M |
|
|
AGN
22
DELISTED
Allergan plc
AGN
| $618M | 0.52% | 3,674,168 +930,202 | +34% | +$157M |
|
23
Vodafone
VOD
$28.8B
| $584M | 0.49% | 29,323,217 +5,682,906 | +24% | +$113M |
|
24
TSMC
TSM
$1.2T
| $579M | 0.49% | 12,456,082 -1,846,070 | -13% | -$85.8M |
|
25
Entergy
ETR
$39.3B
| $564M | 0.48% | 4,803,133 +484,400 | +11% | +$56.8M |
|